Direkt zum Inhalt
Merck
  • Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol.

Treatment of a tongue lymphangioma with sirolimus after failure of surgical resection and propranolol.

Pediatric blood & cancer (2013-11-23)
Canan Akyüz, Erman Ataş, Ali Varan
ZUSAMMENFASSUNG

Lymphangiomas of the tongue are rare, and their treatment is problematic. A 10 year-old patient with tongue lymphangioma who was previously treated with surgery and propranolol with no response was treated with sirolimus in our department. We used sirolimus with a dose of 1.6 mg/m(2)/day. After 3 months of treatment, the mass had decreased by more than 60%. We continued the treatment for 1 year with a maximum response of 70% decrease in mass. Disease remained stable 6 months after stopping therapy, the latest time of follow-up. Sirolimus appears to be effective in lymphangioma but requires further study.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
(±)-Propranolol -hydrochlorid, ≥99% (TLC), powder
USP
Propranolol -hydrochlorid, United States Pharmacopeia (USP) Reference Standard
Supelco
Propranolol-Hydrochlorid, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Propranolol -hydrochlorid, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
(±)-Propranolol -hydrochlorid, analytical standard
Propranolol -hydrochlorid, European Pharmacopoeia (EP) Reference Standard